NEW OPTIONS IN THE TREATMENT OF ARVI
ARVI is the most common infectious disease in developed countries. Every average adult suffers from ARVI at least 2-3 times per year, an average child - up to 6-10 times. ARVI is caused by various pathogens, including at least five different groups of viruses (parainfluenza viruses, influenza, adenoviruses, rhinoviruses). The infection is transmitted by airborne droplets and by contact, for example, by shaking hands. At the initial stage of the disease, the virus reproduces itself in the "gates of infection": nasal cavity, nasopharynx and larynx. Sometimes the process impacts also the mucous membranes of the eyes and gastrointestinal tract. After the virus gets into blood, the following symptoms of toxicity can be observed: fever, headache, aches in back and limbs. Clinicians are in need of medicines that decrease manifestations of ARVI. Aerus aerosol (aprotinin) is a novelty in the outpatient therapy. This finely dispersed solution has antiviral and anti-inflammatory action.